OxySure (OXYS) Appoints Christopher Kaplan to Its Strategic Advisory Board

Frisco, Texas, October 6, 2015 – OxySure Systems, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology and other innovative medical solutions, today announced that it has appointed Christopher Kaplan to its Strategic Advisory Board.

Mr. Kaplan is currently President of Cajetan, LLC, an independent healthcare consulting firm working with companies to deliver better value for patients, fuel innovation, enhance the impact and execution of marketing and sales initiatives, and reduce the cost and complexity of operating systems.

Prior to Cajetan, Mr. Kaplan spent two years with Boehringer Ingelheim as Senior Vice President and Chief Marketing Officer. That followed 12 years at Novartis in both the US and Europe. Mr. Kaplan began at Novartis as Global Head of the Cardiovascular and Metabolic Business Franchise in Basel Switzerland, then moved to Head the Nordic Region Cluster and General Manager in Stockholm Sweden, and then became Head of Northern and Central Europe and Region Europe Marketing & Sales back in Basel. He returned to the US as President, Cardiovascular & Metabolic Operating Unit, in E. Hanover New Jersey, and then served as President and General Manager of the East Operating Unit, also in E. Hanover.

Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various roles in US sales and sales management and then in US marketing. He began his international experience in Paris as the Cardiovascular Marketing Director for Europe and then progressed to his last role at Bristol-Myers Squibb as Marketing and Sales Director in Rome, Italy.

Mr. Kaplan is a graduate of Columbia University, holds a Masters of Science Degree from the University of Pennsylvania, and undertook post-graduate studies at INSEAD, Fontainebleu, France. He has also completed executive education programs at Harvard, Wharton and the London Business School.

Julian T. Ross, CEO of OxySure said, "We are continuing our plan to forward-structure our Strategic Advisory Board to strengthen our collective expertise in healthcare marketing, sales and business development. Chris has a formidable resume and proven track record of success in pharmaceutical and medical sales and marketing. His experience in international business is clearly going to be an asset to OxySure as we continue our international expansion, especially in Europe. His depth and breadth of experience in healthcare sales and marketing and his dedication to healthcare innovation will significantly enhance OxySure’s ability to access the significant opportunities available to it."

Mr. Kaplan said, "I am very pleased to be joining the OxySure Strategic Advisory Board at this inflection point in the Company's growth and history. I am impressed with the achievements OxySure has made so far and I am excited to contribute to new successes going forward."

The current list of Strategic Advisory Board members is located here: http://oxysure.com/aed/index.php/strategic-advisory-board

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products. www.OxySure.com

Forward-Looking Statements

Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management’s control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Systems, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Systems, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014.

Contacts:

Renmark Financial Communications, Inc.                         Redchip Companies, Inc.

Bettina Filippone: bfilippone@renmarkfinancial.com            Jon Cunningham: jon@redchip.com

Tel.: (416) 644-2020 or (514) 939-3989                                 800-733-2447, ext. 107

www.renmarkfinancial.com/                                                   www.redchip.com/

Tags: